位置:首页 > 蛋白库 > KC1D_MOUSE
KC1D_MOUSE
ID   KC1D_MOUSE              Reviewed;         415 AA.
AC   Q9DC28; Q3TZK2; Q99KK4;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   03-AUG-2022, entry version 169.
DE   RecName: Full=Casein kinase I isoform delta;
DE            Short=CKI-delta;
DE            Short=CKId;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10848614, ECO:0000269|PubMed:17101137, ECO:0000269|PubMed:19414593, ECO:0000269|PubMed:20192920};
DE   AltName: Full=Tau-protein kinase CSNK1D;
DE            EC=2.7.11.26 {ECO:0000250|UniProtKB:P48730};
GN   Name=Csnk1d; Synonyms=Hckid;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Bone marrow, Lung, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION AS PER1 KINASE, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=10848614; DOI=10.1128/mcb.20.13.4888-4899.2000;
RA   Vielhaber E., Eide E., Rivers A., Gao Z.-H., Virshup D.M.;
RT   "Nuclear entry of the circadian regulator mPER1 is controlled by mammalian
RT   casein kinase I epsilon.";
RL   Mol. Cell. Biol. 20:4888-4899(2000).
RN   [4]
RP   IDENTIFICATION IN A COMPLEX WITH CLOCK; PER1; PER2; CRY1; CRY2; CSNK1D AND
RP   CSNK1E.
RX   PubMed=11779462; DOI=10.1016/s0092-8674(01)00610-9;
RA   Lee C., Etchegaray J.-P., Cagampang F.R.A., Loudon A.S.I., Reppert S.M.;
RT   "Posttranslational mechanisms regulate the mammalian circadian clock.";
RL   Cell 107:855-867(2001).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=12924632; DOI=10.1078/0171-9335-00323;
RA   Maritzen T., Loehler J., Deppert W., Knippschild U.;
RT   "Casein kinase I delta (CKIdelta) is involved in lymphocyte physiology.";
RL   Eur. J. Cell Biol. 82:369-378(2003).
RN   [6]
RP   FUNCTION IN SYNAPTIC TRANSMISSION.
RX   PubMed=16014721; DOI=10.1523/jneurosci.1082-05.2005;
RA   Chergui K., Svenningsson P., Greengard P.;
RT   "Physiological role for casein kinase 1 in glutamatergic synaptic
RT   transmission.";
RL   J. Neurosci. 25:6601-6609(2005).
RN   [7]
RP   FUNCTION AS SNAPIN KINASE, SUBCELLULAR LOCATION, INTERACTION WITH SNAPIN,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=17101137; DOI=10.1016/j.febslet.2006.10.068;
RA   Wolff S., Stoeter M., Giamas G., Piesche M., Henne-Bruns D., Banting G.,
RA   Knippschild U.;
RT   "Casein kinase 1 delta (CK1delta) interacts with the SNARE associated
RT   protein snapin.";
RL   FEBS Lett. 580:6477-6484(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-382, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [9]
RP   FUNCTION IN CIRCADIAN CLOCK, DISRUPTION PHENOTYPE, CATALYTIC ACTIVITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19414593; DOI=10.1128/mcb.00338-09;
RA   Etchegaray J.P., Machida K.K., Noton E., Constance C.M., Dallmann R.,
RA   Di Napoli M.N., DeBruyne J.P., Lambert C.M., Yu E.A., Reppert S.M.,
RA   Weaver D.R.;
RT   "Casein kinase 1 delta regulates the pace of the mammalian circadian
RT   clock.";
RL   Mol. Cell. Biol. 29:3853-3866(2009).
RN   [10]
RP   FUNCTION IN CIRCADIAN CLOCK, AND DISRUPTION PHENOTYPE.
RX   PubMed=19948962; DOI=10.1073/pnas.0906651106;
RA   Lee H., Chen R., Lee Y., Yoo S., Lee C.;
RT   "Essential roles of CKIdelta and CKIepsilon in the mammalian circadian
RT   clock.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:21359-21364(2009).
RN   [11]
RP   FUNCTION AS DNMT1 KINASE, INTERACTION WITH DNMT1, AND CATALYTIC ACTIVITY.
RX   PubMed=20192920; DOI=10.1042/bj20091856;
RA   Sugiyama Y., Hatano N., Sueyoshi N., Suetake I., Tajima S., Kinoshita E.,
RA   Kinoshita-Kikuta E., Koike T., Kameshita I.;
RT   "The DNA-binding activity of mouse DNA methyltransferase 1 is regulated by
RT   phosphorylation with casein kinase 1delta/epsilon.";
RL   Biochem. J. 427:489-497(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-382 AND SER-383, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Kidney, Lung, Pancreas, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [13]
RP   FUNCTION IN CIRCADIAN CLOCK.
RX   PubMed=20421981; DOI=10.1371/journal.pone.0010303;
RA   Etchegaray J.-P., Yu E.A., Indic P., Dallmann R., Weaver D.R.;
RT   "Casein kinase 1 delta (CK1delta) regulates period length of the mouse
RT   suprachiasmatic circadian clock in vitro.";
RL   PLoS ONE 5:E10303-E10303(2010).
RN   [14]
RP   FUNCTION IN DOPAMINE RECEPTORS.
RX   PubMed=20145109; DOI=10.1073/pnas.0915173107;
RA   Zhou M., Rebholz H., Brocia C., Warner-Schmidt J.L., Fienberg A.A.,
RA   Nairn A.C., Greengard P., Flajolet M.;
RT   "Forebrain overexpression of CK1delta leads to down-regulation of dopamine
RT   receptors and altered locomotor activity reminiscent of ADHD.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4401-4406(2010).
RN   [15]
RP   FUNCTION IN CIRCADIAN CLOCK, AND DEPHOSPHORYLATION.
RX   PubMed=21930935; DOI=10.1073/pnas.1107178108;
RA   Lee H.M., Chen R., Kim H., Etchegaray J.P., Weaver D.R., Lee C.;
RT   "The period of the circadian oscillator is primarily determined by the
RT   balance between casein kinase 1 and protein phosphatase 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:16451-16456(2011).
RN   [16]
RP   MUTAGENESIS OF THR-44.
RX   PubMed=23636092; DOI=10.1126/scitranslmed.3005784;
RA   Brennan K.C., Bates E.A., Shapiro R.E., Zyuzin J., Hallows W.C., Huang Y.,
RA   Lee H.Y., Jones C.R., Fu Y.H., Charles A.C., Ptacek L.J.;
RT   "Casein kinase idelta mutations in familial migraine and advanced phase.";
RL   Sci. Transl. Med. 5:183ra56-183ra56(2013).
RN   [17]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-375, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
CC   -!- FUNCTION: Essential serine/threonine-protein kinase that regulates
CC       diverse cellular growth and survival processes including Wnt signaling,
CC       DNA repair and circadian rhythms. It can phosphorylate a large number
CC       of proteins. Casein kinases are operationally defined by their
CC       preferential utilization of acidic proteins such as caseins as
CC       substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU,
CC       TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1,
CC       PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. In
CC       balance with PP1, determines the circadian period length through the
CC       regulation of the speed and rhythmicity of PER1 and PER2
CC       phosphorylation. Controls PER1 and PER2 nuclear transport and
CC       degradation. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3
CC       ubiquitin ligase-mediated ubiquitination and subsequent degradation.
CC       DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation
CC       of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation.
CC       Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that
CC       controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear
CC       export. Triggers down-regulation of dopamine receptors in the
CC       forebrain. Activates DCK in vitro by phosphorylation. TOP2A
CC       phosphorylation favors DNA cleavable complex formation. May regulate
CC       the formation of the mitotic spindle apparatus in extravillous
CC       trophoblast. Modulates connexin-43/GJA1 gap junction assembly by
CC       phosphorylation. Probably involved in lymphocyte physiology. Regulates
CC       fast synaptic transmission mediated by glutamate.
CC       {ECO:0000269|PubMed:10848614, ECO:0000269|PubMed:16014721,
CC       ECO:0000269|PubMed:17101137, ECO:0000269|PubMed:19414593,
CC       ECO:0000269|PubMed:19948962, ECO:0000269|PubMed:20145109,
CC       ECO:0000269|PubMed:20192920, ECO:0000269|PubMed:20421981,
CC       ECO:0000269|PubMed:21930935}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10848614, ECO:0000269|PubMed:17101137,
CC         ECO:0000269|PubMed:19414593, ECO:0000269|PubMed:20192920};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000305|PubMed:20192920};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10848614,
CC         ECO:0000269|PubMed:17101137, ECO:0000269|PubMed:19414593,
CC         ECO:0000269|PubMed:20192920};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000305|PubMed:20192920};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[tau protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [tau protein]; Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA-
CC         COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26;
CC         Evidence={ECO:0000250|UniProtKB:P48730};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12802;
CC         Evidence={ECO:0000250|UniProtKB:P48730};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[tau protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[tau protein]; Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703,
CC         Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.26; Evidence={ECO:0000250|UniProtKB:P48730};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53905;
CC         Evidence={ECO:0000250|UniProtKB:P48730};
CC   -!- ACTIVITY REGULATION: Exhibits substrate-dependent heparin activation.
CC       Drug-mediated inhibition leads to a delay of the oscillations with the
CC       magnitude of this effect dependent upon the timing of drug
CC       administration. Inhibited by phosphorylation (By similarity).
CC       {ECO:0000250|UniProtKB:P48730}.
CC   -!- SUBUNIT: Monomer (By similarity). Component of the circadian core
CC       oscillator, which includes the CRY proteins, CLOCK, or NPAS2,
CC       ARNTL/BMAL1 or ARNTL2/BMAL2, CSNK1D and/or CSNK1E, TIMELESS and the PER
CC       proteins (PubMed:11779462). Interacts directly with PER1 and PER2 which
CC       may lead to their degradation (By similarity). Interacts with MAP1A (By
CC       similarity). Interacts with MAPT/TAU, DBNDD2, AIB1/NCOA3 and ESR1 (By
CC       similarity). Interacts with AKAP9/AKAP450; this interaction promotes
CC       centrosomal subcellular location (By similarity). Binds to tubulins in
CC       mitotic cells upon DNA damage (By similarity). Interacts with GJA1 (By
CC       similarity). Interacts with SNAPIN (PubMed:17101137). Interacts with
CC       DNMT1 (PubMed:20192920). Interacts with DDX3X; this interaction
CC       enhances CSNK1D kinase activity in vitro, but it is unclear whether
CC       this interaction is physiologically relevant (By similarity).
CC       {ECO:0000250|UniProtKB:P48730, ECO:0000250|UniProtKB:Q06486,
CC       ECO:0000269|PubMed:11779462, ECO:0000269|PubMed:17101137,
CC       ECO:0000269|PubMed:20192920}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:10848614, ECO:0000269|PubMed:17101137,
CC       ECO:0000269|PubMed:19414593}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250}. Cytoplasm, perinuclear
CC       region {ECO:0000250}. Cell membrane {ECO:0000250}. Cytoplasm,
CC       cytoskeleton, spindle {ECO:0000250}. Golgi apparatus {ECO:0000250}.
CC       Note=Localized at mitotic spindle microtubules, and at the centrosomes
CC       and interphase in interphase cells. Recruited to the spindle apparatus
CC       and the centrosomes in response to DNA-damage. Correct subcellular
CC       localization requires kinase activity (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9DC28-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9DC28-2; Sequence=VSP_010254;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously. However, kinase activity is
CC       not uniform, with highest kinase activity in splenocytes.
CC       {ECO:0000269|PubMed:12924632}.
CC   -!- PTM: Autophosphorylated on serine and threonine residues; this
CC       autophosphorylation represses activity. Reactivated by phosphatase-
CC       mediated dephosphorylation. May be dephosphorylated by PP1.
CC   -!- DISRUPTION PHENOTYPE: Lethal. There are fewer embryos than expected at
CC       late stages of gestation; they weigh about 30% less than control
CC       animals, but appear otherwise normal. Mice die shortly after birth.
CC       Tissue-specific disruption increases the half-life of PER2 protein and
CC       alters circadian protein expression dynamics.
CC       {ECO:0000269|PubMed:19414593, ECO:0000269|PubMed:19948962}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. Casein kinase I subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK004606; BAB23405.1; -; mRNA.
DR   EMBL; AK088642; BAC40472.1; -; mRNA.
DR   EMBL; AK152721; BAE31444.1; -; mRNA.
DR   EMBL; AK157812; BAE34206.1; -; mRNA.
DR   EMBL; BC004604; AAH04604.1; -; mRNA.
DR   CCDS; CCDS25762.1; -. [Q9DC28-1]
DR   CCDS; CCDS25763.1; -. [Q9DC28-2]
DR   PIR; S47616; S47616.
DR   RefSeq; NP_620690.1; NM_139059.2. [Q9DC28-1]
DR   PDB; 4JJR; X-ray; 2.41 A; A/B=1-299.
DR   PDB; 5X17; X-ray; 2.00 A; A/B=1-294.
DR   PDBsum; 4JJR; -.
DR   PDBsum; 5X17; -.
DR   AlphaFoldDB; Q9DC28; -.
DR   SMR; Q9DC28; -.
DR   BioGRID; 222545; 24.
DR   DIP; DIP-47809N; -.
DR   IntAct; Q9DC28; 21.
DR   MINT; Q9DC28; -.
DR   STRING; 10090.ENSMUSP00000018274; -.
DR   ChEMBL; CHEMBL5175; -.
DR   iPTMnet; Q9DC28; -.
DR   PhosphoSitePlus; Q9DC28; -.
DR   SwissPalm; Q9DC28; -.
DR   EPD; Q9DC28; -.
DR   jPOST; Q9DC28; -.
DR   MaxQB; Q9DC28; -.
DR   PaxDb; Q9DC28; -.
DR   PeptideAtlas; Q9DC28; -.
DR   PRIDE; Q9DC28; -.
DR   ProteomicsDB; 263482; -. [Q9DC28-1]
DR   ProteomicsDB; 263483; -. [Q9DC28-2]
DR   Antibodypedia; 4210; 376 antibodies from 40 providers.
DR   DNASU; 104318; -.
DR   Ensembl; ENSMUST00000018274; ENSMUSP00000018274; ENSMUSG00000025162. [Q9DC28-1]
DR   Ensembl; ENSMUST00000070575; ENSMUSP00000070721; ENSMUSG00000025162. [Q9DC28-2]
DR   GeneID; 104318; -.
DR   KEGG; mmu:104318; -.
DR   UCSC; uc007mvb.1; mouse. [Q9DC28-1]
DR   CTD; 1453; -.
DR   MGI; MGI:1355272; Csnk1d.
DR   VEuPathDB; HostDB:ENSMUSG00000025162; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   GeneTree; ENSGT00940000153536; -.
DR   HOGENOM; CLU_019279_2_2_1; -.
DR   InParanoid; Q9DC28; -.
DR   OMA; IFDWTFL; -.
DR   PhylomeDB; Q9DC28; -.
DR   TreeFam; TF300544; -.
DR   BRENDA; 2.7.11.1; 3474.
DR   Reactome; R-MMU-204005; COPII-mediated vesicle transport.
DR   Reactome; R-MMU-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-MMU-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-MMU-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-MMU-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-MMU-380320; Recruitment of NuMA to mitotic centrosomes.
DR   Reactome; R-MMU-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-MMU-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   Reactome; R-MMU-8854518; AURKA Activation by TPX2.
DR   BioGRID-ORCS; 104318; 3 hits in 77 CRISPR screens.
DR   ChiTaRS; Csnk1d; mouse.
DR   PRO; PR:Q9DC28; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   RNAct; Q9DC28; protein.
DR   Bgee; ENSMUSG00000025162; Expressed in paneth cell and 273 other tissues.
DR   ExpressionAtlas; Q9DC28; baseline and differential.
DR   Genevisible; Q9DC28; MM.
DR   GO; GO:0005813; C:centrosome; ISO:MGI.
DR   GO; GO:0036064; C:ciliary basal body; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:MGI.
DR   GO; GO:0043005; C:neuron projection; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0005819; C:spindle; ISO:MGI.
DR   GO; GO:0005876; C:spindle microtubule; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; ISO:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; ISO:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:MGI.
DR   GO; GO:0050321; F:tau-protein kinase activity; ISO:MGI.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0007030; P:Golgi organization; ISO:MGI.
DR   GO; GO:0007020; P:microtubule nucleation; ISO:MGI.
DR   GO; GO:1905515; P:non-motile cilium assembly; IMP:MGI.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISO:MGI.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1905426; P:positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation; IC:ParkinsonsUK-UCL.
DR   GO; GO:0071539; P:protein localization to centrosome; ISO:MGI.
DR   GO; GO:0061512; P:protein localization to cilium; ISO:MGI.
DR   GO; GO:0034067; P:protein localization to Golgi apparatus; ISO:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0051225; P:spindle assembly; ISO:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Cell membrane; Cytoplasm; Cytoskeleton; Golgi apparatus; Kinase; Membrane;
KW   Methylation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN           1..415
FT                   /note="Casein kinase I isoform delta"
FT                   /id="PRO_0000192834"
FT   DOMAIN          9..277
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          278..364
FT                   /note="Centrosomal localization signal (CLS)"
FT                   /evidence="ECO:0000250"
FT   REGION          301..415
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          317..342
FT                   /note="Autoinhibitory"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        301..320
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        342..359
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        380..415
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        128
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         15..23
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         38
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48730"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48730"
FT   MOD_RES         370
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06486"
FT   MOD_RES         375
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         384
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48730"
FT   MOD_RES         407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48730"
FT   MOD_RES         411
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48730"
FT   VAR_SEQ         400..415
FT                   /note="IPGRVASSGLQSVVHR -> NSIPFEHHGK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16141072"
FT                   /id="VSP_010254"
FT   MUTAGEN         44
FT                   /note="T->A: Increases pain sensitivity; reduces threshold
FT                   for induction of cortical spreading depression; increases
FT                   arterial dilation during cortical spreading depression and
FT                   increases spontaneous and evoked calcium signaling in
FT                   astrocytes."
FT                   /evidence="ECO:0000269|PubMed:23636092"
FT   CONFLICT        313
FT                   /note="E -> G (in Ref. 1; BAB23405)"
FT                   /evidence="ECO:0000305"
FT   TURN            6..8
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          9..16
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          19..28
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   TURN            29..32
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          33..41
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           49..58
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   TURN            59..61
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          68..74
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          77..83
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           89..95
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   TURN            96..98
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           102..121
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           131..133
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          134..136
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          145..147
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   TURN            159..161
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           182..185
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           192..208
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   TURN            212..215
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           221..233
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           237..240
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   TURN            241..243
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           247..257
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           266..279
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   HELIX           289..291
FT                   /evidence="ECO:0007829|PDB:5X17"
FT   STRAND          295..297
FT                   /evidence="ECO:0007829|PDB:4JJR"
FT   MOD_RES         Q9DC28-2:401
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250"
SQ   SEQUENCE   415 AA;  47316 MW;  B97F04AF9EB466D2 CRC64;
     MELRVGNRYR LGRKIGSGSF GDIYLGTDIA AGEEVAIKLE CVKTKHPQLH IESKIYKMMQ
     GGVGIPTIRW CGAEGDYNVM VMELLGPSLE DLFNFCSRKF SLKTVLLLAD QMISRIEYIH
     SKNFIHRDVK PDNFLMGLGK KGNLVYIIDF GLAKKYRDAR THQHIPYREN KNLTGTARYA
     SINTHLGIEQ SRRDDLESLG YVLMYFNLGS LPWQGLKAAT KRQKYERISE KKMSTPIEVL
     CKGYPSEFAT YLNFCRSLRF DDKPDYSYLR QLFRNLFHRQ GFSYDYVFDW NMLKFGASRA
     ADDAERERRD REERLRHSRN PATRGLPSTA SGRLRGTQEV APPTPLTPTS HTANTSPRPV
     SGMERERKVS MRLHRGAPVN VSSSDLTGRQ DTSRMSTSQI PGRVASSGLQ SVVHR
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024